CMPX

Compass Therapeutics, Inc. (CMPX) | Rumor.io

Compass Therapeutics

CMPX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,268

Bullish sentiment (50-day avg)59%

Price to earnings ratio-2.65

Market capitalization199.9M

Earnings per share-0.39

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-66.5M

Social

What share of all stock conversation is about CMPX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Sep 23

The FDA's response to Compass Therapeutics' filing is puzzling, with some experts questioning the agency's decision and the company's strategy.
The company's Phase 1b data for tovecimig in the second-line biliary tract cancer setting shows a median Duration of Response of 9.4 months, indicating a promising path forward.
The stock price has been volatile, with a 30.8% decline after the filing, but some analysts and investors remain optimistic, citing the drug's potential and the company's strategy.

Generated by AI

Sentiment

Of the messages about CMPX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	66.67% +15.65	58.68% -4.11	70.67% -17.53
Bearish	—	33.33% -15.65	41.32% +4.11	29.33% +17.53

Bullish· Aug 7

The stock has shown a strong start, with investors maintaining buys and the price point looking good at $6-7.
There is a bullish setup with a momentum shift brewing, and the price is still considered cheap at $1.99, offering an opportunity for a fast move.
The stock's price is attractive, and there is a bullish tone, with a potential surge likely in the short term, making it a time-sensitive entry.

Bearish· Apr 27

The asset's recent performance is compared unfavorably to a similar company, with the implication that it may not be able to recover.
The company's data release may be disappointing, with potential consequences for the stock price, including a decline of up to 60%.
The stock's price may be due for a significant decline, with some investors expecting it to drop to $2.50 in a short period of time.

Generated by AI

Topics

Of the messages about CMPX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	80.22%
Technical Analysis	—	0%	0%	4.02%
Analysts	—	0%	0%	14.46%
Controversies	—	0%	0%	0.68%
Earnings	—	0%	0%	0.34%
Macro	—	0%	0%	0.27%

Analysts· May 24

Analysts project CMPX to reach a minimum of $4 within a year, with some estimates as high as $30.
The stock is expected to experience significant volume on Monday.
Analysts' projections are available for review on platforms such as Webull and Robinhood.

Announcements· May 1

Compass Therapeutics, Inc. ($CMPX) has corrected its Form 4 filing to reflect that its General Counsel and Chief Accounting Officer purchased shares on the open market, not as stock grants.
The company's chemotherapy drug for bile duct cancer, tovecimig (CTX-009), has completed Phase 2 and 3 trials and is set to be discussed with the FDA in advance of a planned BLA submission.
Approval for tovecimig is expected in 2027, following the planned meeting with the FDA.

Generated by AI

Community

Of the messages about CMPX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	40.19%	39.97%	22.56%
Newcomers	0%	59.81%	60.03%	77.44%

Regulars· Sep 23

The FDA's request for a new trial is being met with skepticism by some regulars, who argue that the drug has already shown promise in its Phase 1b data and that a new trial would be unnecessary.
The company's valuation is low, with some regulars suggesting that it's almost trading at cash value, making it an attractive investment opportunity.
The regulars are optimistic about the potential for Compass Therapeutics to replicate the success of its early-stage study in a larger trial, citing the impressive median Duration of Response of 9.4 months in the second-line biliary tract cancer setting.

Newcomers· Sep 22

The FDA has recommended that Compass Therapeutics conduct a trial to demonstrate a survival benefit prior to submitting a BLA, which may delay approval and is a major concern for the company.
The COMPANION-002 data show that tovecimig + paclitaxel has a response rate of 18.0% compared to 5.3% with paclitaxel alone, with strong statistical significance, but this may not be enough to demonstrate a survival benefit.
The FDA's recommendation creates a regulatory inflection point, and Compass is preparing its application and engaging with regulators, backed by positive clinical results and an urgent unmet medical need.

Generated by AI

News

Compass Therapeutics CAO Neil Lerner buys $2,849 in CMPX shares

4d agoInvesting.com

Compass Therapeutics Shares Drop After Downgrade From Wedbush

6d agoYahoo Finance

Compass Therapeutics stock downgraded at Wedbush (CMPX:NASDAQ)

Compass Therapeutics (CMPX) stock slides as Wedbush downgrades the company on FDA call for a new study for lead asset tovecimig. Read more here.

6d agoSeeking Alpha

Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity (NASDAQ:CMPX)

6d agoSeeking Alpha

Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’

Several analysts slashed their price targets on Compass Therapeutics after the FDA requested an additional trial for its cancer drug.

6d agofinance.yahoo.com

This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Autoliv (NYSE:ALV)

Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; price targets for CMPX and PCG were cut.

6d agoBenzinga

Also Discussed

Investors talking about CMPX also mention

#	Name	Attention
1	Elicio Therapeutics Inc.ELTX	0%0
2	IDEAYA Biosciences Inc.IDYA	0%-0.01
3	Grace Therapeutics, Inc.GRCE	0%new
4	Replimune Group, Inc.REPL	0%0
5	Erasca Inc.ERAS	0%0
6	Zentalis Pharmaceuticals, Inc.ZNTL	0%new
7	Annexon Inc.ANNX	0%+0
8	Alzamend Neuro, Inc.ALZN	0%0
9	Connect Biopharma Holdings LimitedCNTB	0%+0
10	Argent Focused Small Cap ETFALIL	0%0

Compass Therapeutics, Inc.

Healthcare
Biotechnology

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for cancer. The company concentrates on oncology programs that target angiogenesis, immune activation, and tumor-driven immunosuppression, with product candidates designed to address critical biological pathways involved in anti-tumor responses. Its current pipeline includes bispecific and monoclonal antibody programs such as tovecimig, CTX-471, CTX-8371, and CTX-10726, reflecting a platform built around antibody discovery and engineering. Compass Therapeutics uses proprietary technologies to identify and optimize therapeutic leads and to create modular, manufacturable bispecific candidates. The company plays a specialized role in the biotechnology market by advancing immuno-oncology research into clinical development, with a focus on solid tumors and other cancer indications.

Website

Location

80 Guest Street

Boston, MA, 02135

United States

Social

What share of all stock conversation is about CMPX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Sep 23

The FDA's response to Compass Therapeutics' filing is puzzling, with some experts questioning the agency's decision and the company's strategy.
The company's Phase 1b data for tovecimig in the second-line biliary tract cancer setting shows a median Duration of Response of 9.4 months, indicating a promising path forward.
The stock price has been volatile, with a 30.8% decline after the filing, but some analysts and investors remain optimistic, citing the drug's potential and the company's strategy.

Generated by AI

Sentiment

Of the messages about CMPX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	66.67% +15.65	58.68% -4.11	70.67% -17.53
Bearish	—	33.33% -15.65	41.32% +4.11	29.33% +17.53

Bullish· Aug 7

The stock has shown a strong start, with investors maintaining buys and the price point looking good at $6-7.
There is a bullish setup with a momentum shift brewing, and the price is still considered cheap at $1.99, offering an opportunity for a fast move.
The stock's price is attractive, and there is a bullish tone, with a potential surge likely in the short term, making it a time-sensitive entry.

Bearish· Apr 27

The asset's recent performance is compared unfavorably to a similar company, with the implication that it may not be able to recover.
The company's data release may be disappointing, with potential consequences for the stock price, including a decline of up to 60%.
The stock's price may be due for a significant decline, with some investors expecting it to drop to $2.50 in a short period of time.

Generated by AI

Topics

Of the messages about CMPX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	80.22%
Technical Analysis	—	0%	0%	4.02%
Analysts	—	0%	0%	14.46%
Controversies	—	0%	0%	0.68%
Earnings	—	0%	0%	0.34%
Macro	—	0%	0%	0.27%

Analysts· May 24

Analysts project CMPX to reach a minimum of $4 within a year, with some estimates as high as $30.
The stock is expected to experience significant volume on Monday.
Analysts' projections are available for review on platforms such as Webull and Robinhood.

Announcements· May 1

Compass Therapeutics, Inc. ($CMPX) has corrected its Form 4 filing to reflect that its General Counsel and Chief Accounting Officer purchased shares on the open market, not as stock grants.
The company's chemotherapy drug for bile duct cancer, tovecimig (CTX-009), has completed Phase 2 and 3 trials and is set to be discussed with the FDA in advance of a planned BLA submission.
Approval for tovecimig is expected in 2027, following the planned meeting with the FDA.

Generated by AI

Community

Of the messages about CMPX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	40.19%	39.97%	22.56%
Newcomers	0%	59.81%	60.03%	77.44%

Regulars· Sep 23

The FDA's request for a new trial is being met with skepticism by some regulars, who argue that the drug has already shown promise in its Phase 1b data and that a new trial would be unnecessary.
The company's valuation is low, with some regulars suggesting that it's almost trading at cash value, making it an attractive investment opportunity.
The regulars are optimistic about the potential for Compass Therapeutics to replicate the success of its early-stage study in a larger trial, citing the impressive median Duration of Response of 9.4 months in the second-line biliary tract cancer setting.

Newcomers· Sep 22

The FDA has recommended that Compass Therapeutics conduct a trial to demonstrate a survival benefit prior to submitting a BLA, which may delay approval and is a major concern for the company.
The COMPANION-002 data show that tovecimig + paclitaxel has a response rate of 18.0% compared to 5.3% with paclitaxel alone, with strong statistical significance, but this may not be enough to demonstrate a survival benefit.
The FDA's recommendation creates a regulatory inflection point, and Compass is preparing its application and engaging with regulators, backed by positive clinical results and an urgent unmet medical need.

Generated by AI

Compass Therapeutics

Social

Sep 23

Bullish· Aug 7

Bearish· Apr 27

Analysts· May 24

Announcements· May 1

Regulars· Sep 23

Newcomers· Sep 22

Compass Therapeutics CAO Neil Lerner buys $2,849 in CMPX shares

Compass Therapeutics Shares Drop After Downgrade From Wedbush

Compass Therapeutics stock downgraded at Wedbush (CMPX:NASDAQ)

Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity (NASDAQ:CMPX)

Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’

This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Autoliv (NYSE:ALV)

Also Discussed

Compass Therapeutics, Inc.

Company Information

Location

Compass Therapeutics CAO Neil Lerner buys $2,849 in CMPX shares

Compass Therapeutics Shares Drop After Downgrade From Wedbush

Compass Therapeutics stock downgraded at Wedbush (CMPX:NASDAQ)

Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity (NASDAQ:CMPX)

Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’

This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Autoliv (NYSE:ALV)

Also Discussed

Social

Sep 23

Bullish· Aug 7

Bearish· Apr 27

Analysts· May 24

Announcements· May 1

Regulars· Sep 23

Newcomers· Sep 22